March 9, 2010 Posted by Anonymous
(Indiana University) Women's responsiveness to the second-line breast cancer drug fulvestrant may depend on whether the cancer cells are expressing two key proteins, Indiana University Bloomington scientists report in this month's Cancer Biology & Therapy. (source: Eurekalert.org) - RSS news feeds and Widgets on Feedzilla.com

Comments

Post new comment

Mollom CAPTCHA (play audio CAPTCHA)
Type the characters you see in the picture above; if you can't read them, submit the form and a new image will be generated.